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Abstract 
The emergence of ESBL producing Escherichia coli in clinical isolates is posing a 
serious threat for treating nosocomial infections. The aim of the study was to 
determine the frequency of extended spectrum β-lactamase (ESBL) producing  
Escherichia coli isolated from clinical specimens in several teaching and general  
hospitals in Sana'a city, Yemen, and to compare the phenotypic methods used for the 
characterization of ESBL producing strains. This cross sectional observational study 
was conducted from 1
st
 July to 28
th
 of August 2017, at the Department of Medical 
microbiology, Faculty of Medicine and Health Sciences, University of Sciences and 
Technology in Sana'a city, Yemen.  A total number of 3500 various clinical samples 
were analyzed during the study period. Escherichia coli  were identified using API 
20E system  and ESBL detection was carried out using double-disk synergy test 
(DDST) and CLSI confirmatory test. Escherichia coli  were isolated from 100 
samples, out of which 63 (63%) were ESBL producers and 37 (37%) were non-ESBL 
producers. The gender distribution of ESBL producing  Escherichia coli  was 35/45 
(77.8%) in males and 28/55 (50.9%) in females. Highest frequency of ESBL 
producing Escherichia coli was detected in sputum (100%), wounds (83.3%) and 
urine (65.7%) samples. Comparison of DDST and CLSI confirmatory test showed 
that 65 (65%) isolates were characterized by DDST and 63 (63%) using CLSI 
confirmatory test. All ESBL-positive isolates were susceptible to imipenem, 
indicating that this agent is the best drug for treating serious infections caused by 
ESBL-producing E.coli.  In conclusion, the present study shows moderately high 
frequency of ESBL producing Escherichia coli among patients suffering from sepsis 
in tertiary hospitals in Sana'a city. DDST was found to be less efficient in ESBL 
detection as compared to CLSI confirmatory test. 
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Introduction  
The difficulties seen in fighting infections caused by drug resistant organisms, 
especially those that have acquired resistance to beta-lactams, such as broad-spectrum 
cephalosporins, have resulted from the extensive use of broad-spectrum antibacterial 
agents. One important resistance mechanism to the beta-lactams, including new 
cephalosporins, is due to the destruction of the antibiotics by extended-spectrum beta-
lactamases (ESBLs).
1
  Extended-spectrum β-lactamases (ESBLs) are plasmid encoded 
enzymes that hydrolyze β-lactam ring and cause resistance to β-lactam antibiotics 
which include third-generation cephalosporins such as ceftriaxone, ceftazidime, 
cefotaxime and the monobactam such as aztreonam.
2
 The most common ESBLs are 
derived from widespread broad-spectrum β-lactamases TEM and SHV. Bacterial 
strains expressing these β-lactamases are presenting great therapeutic challenges. In 
recent years there has been a significant increase in incidence and prevalence of 
ESBL producing bacteria.
3
  In addition, Enterobacteriaceae mainly Escherichia 
coli and Klebsiella spp are one of the most bacteria causes sepsis in human.
1, 2
 High 
resistance rates to antimicrobials used in the treatment of E.coli infections have been 
  
reported worldwide, particularly in developing countries including Yemen.
4
  Genes 
responsible for ESBLs production arise by point mutation at the active site of the 
earlier β-lactamases (e.g. TEM-1 and SHV-1 enzymes), and they are usually plasmid 
mediated.
5,6
 In addition, ESBLs-positive Gram-negative bacteria often carry genes 
that confer high levels of resistance to many other antibiotics (e.g. fluoroquinolones 
and aminoglycosides).
7, 8
  The epidemiology of antibiotic resistant bacteria, however, 
varies due to various factors e.g. region, medical field type of infections, and time 
periods.
8, 9
  Therefore, identification and determination of antimicrobial susceptibility 
of bacterial pathogens in the local healthcare setting may aid the clinicians in 
selecting the appropriate antimicrobial agent (s) to treat infected patients. The aim of 
the study was to determine the frequency of extended spectrum β-lactamase (ESBL) 
producing  Escherichia coli isolated from clinical specimens in several teaching and 
general  hospitals in Sana'a city, Yemen, and to compare the phenotypic methods used 
for the characterization of ESBL producing strains.     
Subjects and Methods 
   An active surveillance cross sectional study was conducted at the Department of 
Medical Microbiology, Faculty of Medicine and Health Sciences, University of 
Sciences and Technology in Sana'a city, Yemen. The population of the study included 
in-patients admitted to three tertiary hospitals in Sana'a city: namely: University of 
Sciences and Technology Hospital, Al-Jumhori hospital, and Al-Kuwait hospital, 
from 1
st
 July to 28
th
 of August 2017.  A total number of 3500 various clinical samples 
were analyzed during the study period. The samples were cultured on solid media as 
Blood, Chocolate and MacConkey agar. Cystine Lysine Electrolyte Deficient Medium 
(CLED) was used only for urine culture samples. Escherichia coli   were identified by 
colonial morphology, Gram’s stain, catalase test, oxidase test and API 20E system 
(bioMerieux). A seven digit number generated on the basis of various biochemical 
reactions of API 20E system was checked by API 20E software to 
confirm Escherichia coli. 
10
  
Antimicrobial Drug Susceptibility Testing 
A bacterial suspension of Escherichia coli   was made according to the 0.5 
McFarland turbidity standard and an even lawn of bacteria was made on the Mueller 
Hinton agar petri plate (90mm). The screening for ESBL Escherichia coli   was 
performed using ceftazidime (30 μg) disk and ceftazidime resistant strains were 
considered as screen positives. DDST was performed by using disks containing 
amoxicillin/ clavulanate on Mueller-Hinton agar plate at a 20 mm distance from the 
indicator drugs; ceftazidime (30 μg) and cefotaxime (30 μg). ESBL production was 
seen by the clavulanate mediated enhancement of the activity of the indicator drug as 
a keyhole effect.
11
  
The CLSI confirmatory tests were performed using disks of ceftazidime (30 μg) and 
cefotaxime (30 μg) alone and in combination with ceftazidime-clavulanate (30/10 μg) 
and cefotaxime-clavulanate (30/10 μg). The CLSI confirmatory test was considered 
positive when the inhibition zone produced by the disks in combination clavulanate 
increased ≥5 mm than the disks without the clavulanate. The results of double disk 
diffusion test and CLSI test were compared. 
Ethical Consideration  
Ethical clearance for the study was taken from the Faculty of Medicine and Health 
Sciences, University of Sciences and Technology Research Review Committee. A 
  
written permission was also taken from the administrative Managers of the included 
hospitals.  
Data analysis  
   The analysis of data was done by Epi Info version 6 statistical program (CDC, 
Atlanta, USA), where the chi-square (χ2) and probability value (p) was calculated for 
the test of significance.  
Results 
The detailed results of this study are presented in 3 tables. Escherichia coli were 
isolated from 100 culture positive samples, out of which 63 (63%) were ESBL 
producers and 37 (37%) were non-ESBL producers (table 2). The frequency of ESBL 
producing  Escherichia coli in male and female patients was 35/45 (77.7%)  
(p=0.005) and 28/55 (51%), respectively. Occurrence of ESBL producing  
Escherichia coli  was found to be highest in the sputum samples 6/6 (100%)  (p=0.05) 
followed by the wound samples 5/6 (83.3%) (0.05), while in urine samples occurrence 
of ESBL producing Escherichia coli was 44/67 (65.7%) (table 1). Antibiotic 
sensitivity test result for isolated Escherichia coli is presented in table 3. All ESBL-
positive isolates were susceptible to imipenem, indicating that this agent is the best 
drug for treating serious infections caused by ESBL-producing E.coli. 
Discussion 
The treatment of infectious diseases is fundamental matter for human health and the 
daily increase in bacterial resistance has raised patients’ costs in recent years. The 
production of ESBLs is also a major risk to the use of the new generation of 
cephalosporins. In the last 20 years, the rate of ESBL production 
by Enterobacteriaceae has raised considerably.
12,13,14
 Among Enterobacteriaceae,  E. 
coli is one of  the most important causative agents of nosocomial infections 
15 
 and E. 
coli  is one of the most isolated bacteria from in-patients in Sana'a hospitals; therefore, 
we selected this bacteria for our study. Occurrences of infection effected by extended 
spectrum beta-lactamase producing E. coli have been widely reported all over the 
world following the widespread use of the expanded spectrum cephalosporins.
16, 17-20
  
In our study, phenotypic screening of ESBL showed that 63% of E. coli   isolates 
were positive for ESBL production. Based on this result, the prevalence of ESBL 
producing E.coli was high. The lower prevalence of ESBLs producing E. coli has 
been reported by a number of previous studies; for example in a study by 
Ramazanzadeh et al. revealed a 34.8% ESBL positive rate among strains of Gram-
negative bacteria
 21
  and Mobasherizadeh et al. showed that among a total of 2035 
consecutive clinical isolates identified as E. coli in Al-Zahra Hospital in Iran, 898 
(44.1%) and 432 (21.2%), were ESBL producers for hospitalized and non-
hospitalized patients, respectively.
22
  However, the rate of ESBL producing E.coli in 
our study roughly similar to that reported  by Bazzaz et al. 
23
 and  by Jalalpoor and 
Mobasherizadeh in Iran which they showed that the prevalence of ESBL positive 
strains of E.coli was 59.2% and 58% respectively.
23, 24
 This varies in prevalence of 
ESBLs from region to region and from hospital to another is uncertain whether this is 
because of the differences in infection control practices between hospitals or to 
differences in the use of new cephalosporins.
16
  Our study, has also demonstrated that 
the rates of ESBLs production in Yemen are similar to that of other countries in our 
area and the world, such as; India (57.1%), Turkey (57%) and published data from 
European countries, such as; France, Italy, the Netherlands, Germany, and Spain, as 
well as in the United States, Australia, Japan, Tanzania, Thailand and Pakistan, which 
showed a higher prevalence of ESBL-producing isolates as in the present study.
22, 25-27
  
  
Feizabadi et al.
1
 found that the rates of resistance for ciprofloxacin, cefepime, 
ceftazidime, and cefotaxime were;  21.4%, 28%, 76% and 84.0%, respectively. The 
comparison of our study results with the above-mentioned study shows that antibiotic 
resistance to four of the previously mentioned antibiotics is  higher in our study in 
which the rates of resistance for ciprofloxacin, cefepime, ceftazidime, and cefotaxime 
were; 47%, 91%, 87%, and 85%, respectively. In addition,  a high resistance rate for 
first line drugs including; amoxacillin, and trimethoprim-sulfamethoxazole were 
found in our study (96% and 66% respectively) this result is similar to  
Mobasherizadeh et al. study, in which both non-hospitalized and hospitalized isolates 
of E.coli  were more resistant to first line drugs including; amoxacillin, and 
trimethoprim-sulfamethoxazole.
22
 Our result, which is comparable with other studies 
in developing countries, is due to the widespread use of these drugs because of their 
low cost and easy administration. Imipenem, amikacin and Nitrofurantoin were the 
most effective antibiotics against hospitalized ESBL-producing E.coli isolates in our 
study. All ESBL-positive isolates were susceptible to imipenem, indicating that this 
agent is the best drug for treating serious infections caused by ESBL-
producing E.coli. Our result is similar to that reported by Gholipour et al. and 
Mobasherizadeh et al. in which  all ESBL-positive isolates were susceptible to 
imipenem, and amikacin.
22,28
   The lower rates observed with nitrofurantoin in our 
study (3%) may be due to less use of the drug in treating bacterial infections 
(including UTIs) in Yemen. Newer antibiotics like third generation cephalosporins 
(e.g. ceftriaxone and cefotaxime) and fluoroquinolones (e.g. ciprofloxacin and 
norfloxacin) have been more widely used in recent years in Yemen. This observation 
can be supported by the findings of the present investigation of high resistance rates to 
ciprofloxacin, cephalosporins such as ceftazidime, ceftriaxone, and cefepime 
among E. coli  (table 3). 
The comparison of DDST and CLSI confirmatory test showed that the higher 
numbers of positive isolates were detected by CLSI confirmatory test (100%) than the 
DDST (95.4%) (4.6% were false positive for ELSB) (table 2). A study conducted by 
collecting 91 ESBL producers from 32 hospitals in Kinki area of Japan reported 
DDST positive for 97.80% of the isolates and was negative for only 2.19% of 
isolates.
29
   Rao et a.l used DDST and CLSI confirmatory test on 126 ESBL screen 
positive isolates. Their result of the DDST method detected 86.5%  and the CLSI 
detected 73.8% of the cases.
30
  Study conducted by Dechen et a.l showed that ESBL 
producers can be detected by DDST and CLSI confirmatory test with equal efficacy. 
Their results showed 100% agreement in DDST and CLSI method for detection of 
ESBL producers.
31
  Another study from India reported 135 screen positive ESBL 
producers. In this study the DDST showed positive results in 126 (93.3%) while CLSI 
in 135 (100%) cases.
32
 These studies support the results of our study where CLSI 
confirmatory test is found to be better than DDST. 
  Conclusion 
In conclusion, high frequency of ESBL producing E.coli was found at our study. 
CLSI confirmatory tests generated better results than DDST. Due to the wide spread 
of ESBL producing strains, it is important to maintain the active surveillance system 
at microbiological laboratories for early detection of ESBL producing organisms. 
Preventive measures to stop the colonel spread of the resistant strains could 
significantly reduce the risk of treatment failure and help in the generation of sound 
epidemiological data. 
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Table 1: The association between ESBL E. coli isolates and sex and sites of infections. 
Factors ESBL positive n=63 P value 
No % 
Sex 
Male n=45 35 77.8 0.005 
Female n=55 28 50.9 0.005 
Site of infections (clinical specimens) 
Urine n=67 44 65.7 0.4 
Wounds n=6 5 83.3 0.05 
Sputum n=6 6 100 0.05 
Pus n=9 4 44.4 0.26 
HVS n=5 2 40 0.27 
Blood n=4 2 50 0.58 
Others specimens 
n=3 
0 0 0.02 
P value significant ≤0.05 
 
 
Table 2: Comparison of DDST and CLSI detection of ESBL (n=100). 
Tests Positive isolates Negative isolates 
No % No % 
Double Disk Synergy test 65 65 35 35 
CLSI confirmatory test 63 63 37 37 
 
 
 
  
Table 3: The percentages of antimicrobial resistance detected among 100 multidrug-resistant E. coli 
isolates. 
Antimicrobial agent (µg) Number Percentage   
%            
Amikacin (30μg) 6 6 
Amoxicillin-Clavulanic  Acid (30 μg)  96 96 
Aztreonam (30 μg) 72 72 
Cefepime (30 μg) 81 81 
Cefepime-Clavulanic Acid (30μg) 91 91 
Cefotaxime (30μg) 85 85 
Ceftazidime (30μg) 87 87 
Ceftazidime-ClavulanicAcid (30µg) 97 97 
Ceftriaxone (10μg) 84 84 
Ciprofloxacin (5 μg) 47 47 
Gentamicin (10μg) 23 23 
Imipeneme (10 µg) 0 0 
Nitrofurantoin (300µg) 3 3 
Norfloxacin (10 µg) 50 50 
Trimethoprim-sulfamethoxazol (25µg) 66 66 
 
 
 
